Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INFINiTE-CV2 interferon beta-1a hyaluronic acid nasal spray trial for COVID-19
ACTRN12622000258752Phase 2Not yet recruiting
- Sponsor
- IVIM Technology
- Start
- Mar 2022
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of interferon beta-1a and hyaluronic acid in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by IVIM Technology. Primary endpoints: Time to resolution of symptoms and Viral clearance. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
interferon beta-1ahyaluronic acid
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ACTRN12622000258752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622000258752.